Uric acid‐lowering effects of sodium‐glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: A systematic review and meta‐analysis

Abstract

BackgroundTo evaluate the effect of a 1 mg/dl reduction in uric acid (UA) on cardiovascular events and mortality in patients treated with sodium‐glucose cotransporter 2 (SGLT2) inhibitors.Research Design and MethodsWe performed a systematic review of the MEDLINE and EMBASE databases searched up to 30 June 2023 (PROSPERO, CRD42022355479) to identify large‐scale SGLT2 inhibitor trials. Random‐effects meta‐analyses were used to pool the estimates.ResultsIn total, five SGLT2 inhibitor trials (31 535 patients, 54% with heart failure) were analysed. Over a median follow‐up of 2.2 years, the mean reduction in UA was −0.79 mg/dl (95% confidence interval (CI), −1.03 to −0.54). Every 1 mg/dl reduction in UA was associated with a significantly lower risk of a composite of cardiovascular death and hospitalization for heart failure [hazard ratio, 0.64 (95% CI, 0.46–0.88)] and hospitalization for heart failure (0.68; 95% CI, 0.62–0.74), with a similar risk of mortality.ConclusionsSGLT2 inhibitors reduced UA levels and cardiovascular events independently of heart failure status.

Association of Serum Uric Acid with Non-Valvular Atrial Fibrillation: A Retrospective Study in China

“…8,9 Serum uric acid (SUA) is produced by purine catabolism, which induces inflammation in vascular endothelial cells and smooth muscle cells, as well as intracellular oxidative stress, leading to endothelial dysfunction and thus affecting thrombosis and inflammatory responses. 10 The current study found that high SUA levels are strongly associated with cardiovascular disease (CVD) and its adverse events, 11,12 and there is an association with traditional cardiovascular risk factors. 13 SUA levels are significantly associated with inflammatory and oxidative stress pathways.…”

Relationship between serum uric acid levels and uric acid lowering therapy with the prognosis of patients with heart failure with preserved ejection fraction: a meta-analysis

“…A systematic review and meta-analysis published in 2021 indicated that serum uric acid is positively associated with the risk of adverse events in chronic HF patients ( 12 ). Another systematic review and meta-analysis demonstrated that every 1 mg/dl reduction in uric acid was associated with a significantly lower risk of a composite of cardiovascular (CV) death and hospitalization for HF ( 13 ). Previous systematic reviews or meta-analyses have focused on the relationship between uric acid levels and the prognosis of HF patients.…”